Propanc Health Group (PPCH) Starts Presentation at LD Micro Main Event
Propanc Health Group (OTC: PPCH) is a development-stage healthcare company that focuses on the development of cancer treatments for patients with pancreatic and colorectal cancer. The company's lead product includes PRP, a patented formulation consisting of two pro-enzymes, such as trypsinogen and chymotrypsinogen, as well as the enzyme amylase designed to synergistically enhance anti-cancer effects. It is also developing a combination of anti-cancer agents working in combination with pro-enzymes, which enhance PRP's anti-cancer effect. For more information, visit the company's website at www.propanc.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array…







